Literature DB >> 3802192

Combination headache: practical experience with a combination of a beta-blocker and an antidepressive.

V Pfaffenrath, U Kellhammer, W Pöllmann.   

Abstract

In the prophylaxis of migraine beta-blockers are commonly used. In the therapy of tension headache (TH) the use of tricyclic antidepressives is widespread. Therefore, from a rational point of view, one should combine an antidepressive and a beta-blocker in the treatment of combination headache (CH), in which patients have both migraine and TH. In an open uncontrolled study, 61 patients with CH received a combination of an antidepressive (amitriptyline) or amitriptyline-N-oxide and a beta-blocker (propranolol or metoprolol) for at least 3 months. The 61 patients kept a diary in which they recorded frequency and duration of migraine attacks and tension headaches. The median migraine attack frequency decreased in the 3 months from four to two and the mean attack duration per month from 2 to 0.7 days. TH frequency was reduced from a median of 21 days to 6 days; TH duration fell from a median of 21 days to 2.7 days. At first sight, this treatment appears to be highly effective, at least when judged by the results at the group level. Nevertheless, in an open uncontrolled study like this, one must be aware of many problems, which are discussed in detail.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3802192     DOI: 10.1177/03331024860060S503

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  3 in total

Review 1.  Therapeutic uses of beta-adrenoceptor blocking drugs in the central nervous system in man.

Authors:  P Turner
Journal:  Postgrad Med J       Date:  1989-01       Impact factor: 2.401

2.  [Studies on the predictive factors of treatment success in combination headache.].

Authors:  V Pfaffenrath; U Niederberger; H Kaube
Journal:  Schmerz       Date:  1989-12       Impact factor: 1.107

Review 3.  [A clinical challenge. Pragmatic treatment of migraine and concomitant depression].

Authors:  T P Jürgens; E Leinisch; H J Koch
Journal:  Schmerz       Date:  2008-02       Impact factor: 1.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.